Opaleye Management Inc., an investment firm recognized as a ten percent owner of Eton Pharmaceuticals, Inc. (NASDAQ:ETON), has reported the sale of approximately $4.77 million worth of common stock. The divestment activity unfolded over several days in early July 2026, with transaction prices for the sold shares ranging between $37.3851 and $38.3728 per share. These sales occur as Eton Pharmaceuticals shares trade near their 52-week high of $38.62, following a substantial 162% return over the past year. According to InvestingPro analysis, the stock remains fairly valued at current levels.
The transaction history begins on July 2, 2026, when Opaleye Management Inc. reported two distinct sales. The first transaction involved 65,000 shares of Eton Pharmaceuticals common stock sold by Opaleye, L.P., an entity for which Opaleye Management Inc. acts as the investment manager and may be deemed to beneficially own the securities. The second sale on the same day involved 25,000 shares sold by a separately managed account, for which Opaleye Management Inc. acts as portfolio manager and may be deemed to beneficially own the securities. Both sales on July 2 were executed at a weighted average price of $37.3851 per share, with individual transaction prices ranging from $37.05 to $37.85.
Subsequent activity occurred on July 6, 2026, when Opaleye, L.P. sold an additional 10,000 shares of Eton Pharmaceuticals common stock at a price of $38.00 per share. The latest reported transactions took place on July 7, 2026. On this date, Opaleye, L.P. sold 20,000 shares, while the separately managed account sold 6,685 shares. These sales were made at a weighted average price of $38.3728 per share, with individual transaction prices ranging from $38.00 to $38.565.
Following these transactions, Opaleye, L.P. holds 2,680,000 shares, and the separately managed account holds 53,315 shares of Eton Pharmaceuticals common stock. Opaleye Management Inc. disclaims beneficial ownership of the reported shares except to the extent of its pecuniary interest. The stock closed at $37.74, down $0.280 or 0.74%, with after-hours trading showing a price of $37.55, down $0.190 or 0.50%.
In other recent news, Eton Pharmaceuticals reported its first-quarter 2026 earnings, presenting a mixed financial outcome. The company achieved a revenue of $24.3 million, which exceeded analyst forecasts by 10.71%. However, the earnings per share came in at $0.05, significantly below the expected $0.19, marking a 73.68% negative surprise. Additionally, Eton Pharmaceuticals announced a supply and distribution agreement with an affiliate of Knight Therapeutics. This agreement grants Eton exclusive U.S. commercialization rights to IMPAVIDO, the only FDA-approved treatment for various forms of leishmaniasis. Furthermore, H.C. Wainwright reiterated its Buy rating for Eton Pharmaceuticals, maintaining a price target of $57.00.